Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose of this study is to determine the safety and efficacy of topical applications of NB-001 as compared to placebo for the treatment of recurrent herpes labialis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: NanoBio Corporation
• Treatments: 5- ((2- (6- Amino- 9H- purin- 9- yl) ethyl) amino) - 1- pentanol; 5-((2-(6-Amino-9H-purin-9-yl) ethyl) amino)-1-pentanol

Criteria

Inclusion Criteria:

• 18 to 80 years of age of either gender

• Good general health

• History of recurrent herpes labialis with at least 3 episodes per year

Exclusion Criteria:

• Pregnant and/or nursing female

• Lesions or irritation on or around the lips that would interfere with recognition of a herpes labialis attack

• Treatment with topical steroids, antivirals, or new topical products on or around the lips in the week prior to the onset of an attack

• Known allergies to topical creams, ointments or medications.

Other protocol-defined inclusion/exclusion criteria may apply